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Abstract: Identification of causal factors that influence fetal growth and anthropometry at birth is
of great importance as they provide information about increased risk of disease throughout life.
The association between maternal genetic polymorphism MTHFR(677)C>T and anthropometry at
birth has been widely studied because of its key role in the one-carbon cycle. MTHFR(677) CT and
TT genotypes have been associated with a greater risk of low birth weight, especially in case of
deficient intake of folic acid during pregnancy. This study aimed to analyze the association between
the maternal MTHFR(677)C>T genetic polymorphism and anthropometry at birth in a population
with adequate folate consumption. We included 694 mother–newborn pairs from a prospective
population-based birth cohort in Spain, in the Genetics, Early life enviroNmental Exposures and
Infant Development in Andalusia (GENEIDA) project. Women were genotyped for MTHFR(677)C>T
SNP by Q-PCR using TaqMan© probes. Relevant maternal and newborn information was obtained
from structured questionnaires and medical records. Results showed that maternal MTHFR(677)C>T
genotype was associated with newborn anthropometry. Genotypes CT or CT/TT showed statisti-
cally significant associations with increased or decreased risk of large-for-gestational-age (LGA) or
small-for-gestational-age (SGA) based on weight and height, depending on the newborn’s sex, as
well as with SGA in premature neonates. The relationships between this maternal genotype and
anthropometry at birth remained despite an adequate maternal folate intake.
Keywords: MTHFR(677)C>T polymorphism; folate; folic acid; anthropometry at birth
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1. Introduction
Anthropometric measurements of infants not only allow for assessing intrauterine
growth, but also help to identify infants with a greater risk of suffering developmental
disorders or diseases in adult life. Fetal ultrasound biometry measurement as well as birth
anthropometry parameters (weight, height, chest circumference and head circumference
adjusted for gestational age) are used as indicators to evaluate intrauterine fetal growth [1].
The terms small for gestational age (SGA) and large for gestational age (LGA) are defined
as a function of whether anthropometric variables are below 10th percentile or above 90th
percentile for gestational age, respectively. Infants born SGA or LGA have been associated
with a significant perinatal morbidity and increased risk of diseases later in life as compared
to infants born adequate for gestational age (AGA) [2–5].
Fetal growth and SGA or LGA results are influenced by different factors including
maternal socio-demographic characteristics, health status, nutritional intake, environmental
exposures, genetic background and gene-environment interactions [6–8].
Among nutrients, folate stands out for its role in fetal growth and placental devel-
opment. Folate is the natural occurring state of folic acid (synthetic form) or vitamin B9,
an essential water-soluble vitamin that must be obtained from diet. The main sources of
folate are citrus fruits, legumes, green vegetables and liver. A daily dose of 400 micrograms
of folic acid supplement is recommended to future mothers from the periconceptional
period to prevent neural tube defects as well as low birth weight and preterm birth that
are known to be associated to insufficient folate consumption during early pregnancy [9].
This supplementary dose is designed to achieve a daily folate intake of at least 600 micro-
grams per day during pregnancy. Folate is crucial during early pregnancy, where folate
requirement increases 5 to 10 fold [10], as it participates in the one-carbon cycle, involved
in synthesis of nucleic acids and aminoacids, cell division, tissue development and DNA
methylation [11,12]. Moreover, as different studies point to potential adverse consequences
of the intake of folic acid above a certain level, the recommended dose of folate intake
during pregnancy is 600 to 1000 micrograms per day [5,13]. Vitamin B12 is also a relevant
micronutrient, as it is cofactor for enzymes participating in the one-carbon cycle. A low
level of maternal B12 together with increased level of homocysteine has been associated
with impaired fetal growth, which suggests that an intake of methyl group donor nutrients
such as folate is necessary in advanced stages of pregnancy [14]. The WHO recommended a
B12 intake of 2.6 µg/day during pregnancy to support daily transfer to the fetus, although
larger intakes (such as 1000 µg B12/day) are devoid of adverse effects [15].
On the other hand, alteration in folate levels can occur as a result of genetic poylmor-
phisms in gene coding for enzymes involved in its metabolism, which may lead to changes
in their catalytic activity. One of these enzymes is methylenetetrahydrofolate reductase
(MTHFR), which is often assessed in epidemiological studies due to the direct relationship
between its activity and the levels of folate and also because of its implication in hyper-
homocysteinemia [12,16]. Folate is converted by the MTHFR enzyme into the active form
5-methyltetrahydrofolate (5-MTHF), and carriers of the low activity allele have impaired
lower ability to metabolize folate. Thus, the genetic polymorphism MTHFR(677)C>T
(rs1801133) is responsible for folate availability, and decreased MTHFR enzymatic activity,
together with certain environment conditions during pregnancy such as poor nutrition,
low folate intake, hyperhomocysteinemia and active or passive exposure to tobacco smoke,
have been associated with an increased risk of different adverse birth outcomes [17–19].
We hypothesized that key genetic polymorphisms responsible for folate availability
influence fetal growth in populations with adequate folate intake. Therefore, the aim of
the present study was to assess the association between the maternal MTHFR(677)C>T
genetic polymorphism and anthropometry at birth in the Genetics, Early life enviroNmental
Exposures and Infant Development in Andalusia (GENEIDA) birth cohort. This consists of
a Mediterranean population of pregnant women supplemented with folic acid that reached
the recommended folate dose during pregnancy.
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2. Materials and Methods
2.1. Study Population and Design
This study was conducted on 694 mother/child pairs from the GENEIDA birth cohort.
Pregnant women were recruited in the “Hospital El Poniente” in El Ejido, Almería (South-
east Spain) during the period from April 2014 to November 2017. Women were recruited
in the first trimester of pregnancy (12–13 weeks of gestation) and then followed-up in the
third trimester of pregnancy, at delivery. The inclusion criteria were: 16 years old or older,
intention of giving birth at the reference hospital mentioned above, singleton pregnancy,
pregnancy without assisted reproductive technology, lack of any chronic disease or being
under medical treatment and absence of any language barrier.
2.2. DNA Extraction and Methylenetetrahidropholate Reductase Single Nucleotide Polymorphism
(SNP) MTHFR(677)C>T (rs1801133) Genotyping
Blood samples were collected in the second trimester of pregnancy. Each sample
(4 mL) was centrifuged at 2500 rpm for 15 min and the buffy coat (containing white blood
cells) was carefully removed and stored at −20 ◦C until analysis. DNA was extracted
using the “X-DNA Extraction Kit (XtremBiotech SL, Granada, Spain) following the man-
ufacturer’s instructions. DNA integrity was checked by gel agarose gel electrophoresis.
Quantification of DNA was carried out by spectrophotometry using the NanoPhotome-
terTM P-Class (IMPLEN, Schatzbogen, Germany). A total of 20 ng of dried-down genomic
DNA was used for genotyping. Specific TaqMan® Predesigned SNP Genotyping Assays
(Applied Biosystems, Foster City, CA, USA) was used for the detection of the specific
MTHFR(677)C>T (rs1801133) SNP in a QuantStudio 6 Flex Real-Time PCR System. As
quality control, each series of amplifications included three negative controls without the
DNA template to test for DNA contamination and three previously genotyped samples to
test genotyping consistency.
2.3. Anthropometric Characteristics and Gestational Age
Gestational age and anthropometric measurements (weight, height, head circumfer-
ence and chest circumference) at birth were obtained from medical hospital records. Weight
index was calculated as the ratio of birth weight (grams) to height (cm3) [20].
Size for gestational age was estimated based on Carrascosa et al. 2004 [21] using
neonatal gestational age at delivery, anthropometric measurements (AM: weight, height,
head circumference) and sex. Newborns were categorized into three groups: SGA (AM less
than 10th percentile for gestational age), AGA (AM 10th to 90th percentile for gestational
age; which was the reference group), and LGA (AM greater than 90th percentile for
gestational age).
A suitable alternative to identify SGA was using a chest circumference ≤ 30 cm as
cut-off point.
2.4. Covariates
Information on covariates was obtained from questionnaires administered by personal
interviews in the first and third trimester of pregnancy, and medical records. Covariates
were selected according to clinical relevance and literature review of previous birth co-
hort studies in which association between genetic polymorphisms and birth outcomes
was analyzed.
2.4.1. Dietary Vitamin B12, Folate Intake and Folic Acid Supplementation Use
Information on diet was obtained using an adapted version of the food consumption of
the Andalucian population based on a previously validated food frequency questionnaire
(FFQ) [22,23]. In the first (12–13 weeks) and third trimester (36 weeks) of pregnancy, women
were asked to report about their usual food consumption. The information obtained in the
first trimester included intakes from 6 months pre-pregnancy until 12–13 weeks of gestation
and the information obtained in the third trimester covered intakes between 14 and 36
Nutrients 2021, 13, 831 4 of 15
gestational weeks. The FFQ includes the frequency of consumption and portion sizes for
119 food items, beverages including alcohol drinks, and intake of dietary supplements,
including folic acid and other vitamins. The FFQ had nine options according to individual
frequency consumption of each food or drink item. The i-Diet software (i-Diet; i-diet.es,
Oviedo, Spain) [24] was used to estimate energy and daily nutrients intake (folate and
B12 vitamins among others). Information on supplement intake included brand name,
dosage per day and the start and end dates of consumption. This information was used
to determine supplemental folate dose per day for each woman. Thereafter, data on
background intake of folate from food was estimated according to its bioavailability in
comparison with synthetic folic acid intake from food supplements. Thus, dietary folate
was defined as 60% of the reported folate intake from foods [6,15,25,26]. Accordingly, the
total folate intake in each trimester was calculated as supplemental folic acid +0.6 * folate
intake from food [6]. Total B12 vitamin intake was calculated by the sum of the amount
ingested from food and that from supplements.
A reproducibility and validation study of the FFQ was developed within the same
population of pregnant women. The reproducibility analysis was conducted in a sample of
690 pregnant women who provided food consumption data for the first and third trimester
of pregnancy. The Spearman correlation coefficients for folate and vitamin B12 intake
estimated by the two FFQs were 0.486 and 0.385 p < 0.001, respectively. Validation analysis
of the questionnaires was also carried out in a selected subsample of women (n = 43) who
filled-in three 24-h dietary recalls in addition to the FFQs. The limits of agreement (LoA)
for folate and vitamin B12 were 90.70% and 93.02%, respectively.
2.4.2. Sociodemographic, Lifestyle and Obstetrics Variables
Maternal covariates were obtained from hospital medical records (gestational diabetes
and hypertension) and questionnaires administered by trained interviewers in first and
third trimester of pregnancy. These covariates were maternal height, self-reported pre-
pregnancy weight and weight at week 36 of pregnancy, which allowed for calculation of
weight gain during pregnancy and body mass index (BMI). Data collected on sociodemo-
graphic characteristics included maternal age, maternal education level, employment data,
family income, marital status, parity, planned pregnancy, and lifestyles (tobacco smoking
and alcohol consumption) during the pregnancy.
2.5. Statistical Analyses
The R Project for Statistical Computing (version 4.0.2, R Foundation for Statistical
Computing, Vienna, Austria) was used for imputation of missing values of covariates.
Multivariate imputations by chained equation in R (MICE package) were used to replace
missing information [27]. Ten imputed datasets were generated; the mode was selected for
non-continuous variables and the mean for the remaining variables.
Statistical analyses were performed using the IBM SPSS Statistics v.21 software. Gen-
eral characteristics of the study population were described using geometric mean, arith-
metic mean, standard deviation and 95% confidence interval for continuous variables and
absolute (n value) and relative frequencies (percentage) for categorical variables. Analyses
were stratified by newborn sex.
The Student’s t test was used to compare means of continuous variables with a normal
distribution. The non-parametric Mann–Whitney test was used to compare quantitative
variables that failed to fit a normal distribution. The Chi-squared test was used for qualita-
tive variables comparison (including differences in categorical variables by newborn sex)
and also to examine whether genotype distribution was in Hardy–Weinberg equilibrium.
Bivariate and multinominal logistic regression analyses were used to evaluate associa-
tion (odds ratio, OR) between MTHFR(677)C>T maternal genotypes and anthropometric
variables for gestational age (SGA versus AGA and LGA versus AGA). Homozygous CC
was the reference genotype used. OR greater than 1 was considered a positive association
Nutrients 2021, 13, 831 5 of 15
(risk effect) whereas OR values less than 1 indicated negative association (protective effect).
All models were stratified by newborn sex.
Statistical significance was assumed for p-values < 0.1.
3. Results
The distribution of maternal genotype and allele frequencies is shown in Table 1. No
significant differences were found when comparing by newborn sex. When observed
frequencies were compared to the expected frequencies, no significant deviations from the
Hardy–Weinberg equilibrium (HWE) were observed (p > 0.1).
Table 1. Genotypic and allele frequencies for the MTHFR(677)C > T (rs1801133) polymorphism. Frequencies are shown for






Genotypic and Allele Frequencies





amino acid residue 222
CC = 0.39 CC = 0.40 CC = 0.38
CT = 0.45 CT = 0.45 CT = 0.46
TT = 0.16 TT = 0.15 TT = 0.16
C = 0.62 C = 0.63 C = 0.61
T = 0.38 T = 0.37 T = 0.39
The main clinical and sociodemographic characteristics of the study population are
shown in Tables 2 and 3. Table 2 summarizes information on continuous variables of
newborns and their mothers. Significant differences were found for newborn weight,
height, head circumference and chest circumference when compared by sex (p < 0.01). The
remaining newborn anthropometric measures failed to show significant differences. Mean
total folate and vitamin B12 intakes of pregnant women were within the recommended
range during pregnancy. When compared by sex, mean maternal vitamin B12 intake
during the first trimester of gestation was significantly lower for female newborn infants
(p = 0.055).
Table 2. Clinical and demographic characteristics of the study population (continuous variables).
Characteristic























Height (cm) 50.62 (2.14) 50.57 50.99 (2.18) 50.94 50.23 (2.28) 50.17 <0.001
Head
circumference (cm) 33.73 (1.57) 33.69 33.99 (1.54) 33.96 33.45 (1.55) 33.42 <0.001
Chest
circumference (cm) 32.96 (1.82) 32.91 33.19 (1.83) 33.14 32.72 (1.77) 32.67 0.001
Weight index
(g/cm3) 2.55 (0.25) 2.53 2.54 (0.25) 2.54 2.54 (0.25) 2.53 0.829
Gestational age
(weeks) 39.55 (1.45) 39.52 39.57 (1.46) 39.54 39.52 (1.45) 39.49 0.566
Nutrients 2021, 13, 831 6 of 15
Table 2. Cont.
Characteristic












































10.50 (6.60) 9.37 10.93 (7.92) 9.63 10.04 (5.36) 9.11 0.055
Vitamin B12 intake
(µg/day)
2nd y 3rd Trimester
9.91 (8.16) 8.38 9.74 (7.92) 8.30 10.09 (8.42) 8.47 0.886
Weight gain (g) 11.20 (5.32) * 11.21 (5.76) * 11.20 (4.85) * 0.706
BMI Prepregnancy 24.34 (4.75) 24.02 24.28 (4.34) 24.10 24.38 (5.14) 23.93 0.671
BMI 3rd Trimester 28.53 (4.61) 28.18 28.46 (4.20) 28.17 28.58 (5.01) 28.20 0.533
* Cannot be calculated due to negative values; 1 Student t-test was used for weight and weight index, (normal distributed variables),
whereas the Mann–Whitney test was used for the remaining anthropometric measures (not normally distributed variables); 2 Total folate
intake (calculated as supplemental folic acid + 0.6 * folate intake from food).
Table 3. Clinical and demographic characteristics of the study population (categorical variables).
Characteristic




(n = 339) p-Value 1






SGA 36 (5.2) 19 (5.4) 17 (5.0)
0.782Normal 568 (81.8) 293 (82.5) 275 (81.1)
LGA 90 (13.0) 43 (12.1) 47 (13.9)
Height
SGA 33 (4.8) 13 (3.7) 20 (5.9)
0.079Normal 503 (72.5) 270 (76.1) 233 (68.7)
LGA 158 (22.8) 72 (20.3) 86 (25.4)
Head circumference
SGA 68 (9.8) 29 (8.2) 39 (11.5)
0.315Normal 621 (89.5) 323 (91.0) 298 (87.9)
LGA 5 (0.7) 3 (0.8) v 2 (0.6)
Chest circumference
SGA 24 (3.5) 12 (3.4) 12 (3.5)
0.908Normal 670 (96.5) 343 (96.6) 327 (96.5)
Weight index
SGA 220 (31.7) 116 (32.7) 104 (30.7)
0.799Normal 448 (64.6) 225 (63.4) 223 (65.8)
LGA 26 (3.7) 14 (3.9) 12 (3.5)
Prematurity
Yes 26 (3.7) 14 (3.9) 12 (3.5)
0.779No 668 (96.3) 341 (96.1) 327 (96.5)
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Table 3. Cont.
Characteristic




(n = 339) p-Value 1







Spanish 618 (89.0) 320 (90.1) 298 (87.9)
0.395South American 8 (1.2) 5 (1.4) 3 (0.9)
European (not Spanish) 68 (9.8) 30 (8.5) 38 (11.2)
Education level
No studies 38 (5.5) 18 (5.1) 20 (5.9)
0.898
Primary school 303 (43.7) 154 (43.4) 149 (44.0)
Secondary school 161 (23.2) 86 (54.2) 75 (22.1)
University studies 192 (27.7) 97 (27.3) 95 (28.0)
Smoking during pregnancy
Yes 116 (16.7) 61 (17.2) 55 (16.2)
0.735No 578 (83.3) 294 (82.8) 284 (83.8)
Alcohol consumption during pregnancy
Yes 564 (81.3) 281 (79.2) 283 (83.5)
0.144No 130 (18.7) 74 (20.8) 56 (16.5)
Folate intake pre-pregnancy and 1st Trimester 2
<600 µg/day 162 (23.3) 75 (21.1) 87 (25.7)
0.158≥600 µg/day 532 (76.7) 280 (78.9) 252 (74.3)
Folate intake 2nd and 3rd Trimester 2
<600 µg/day 243 (35.0) 124 (34.9) 119 (35.1)
0.962≥600 µg/day 451 (65.0) 231 (65.1) 220 (64.9)
Gestational diabetes
Yes 37 (5.3) 27 (7.6) 10 (2.9)
0.006No 657 (94.7) 328 (92.4) 329 (97.1)
Hypertension
Yes 14 (2.0) 8 (2.3) 6 (1.8)
0.651No 680 (98.0) 347 (97.7) 333 (98.2)
1 Chi-squared test. 2 Total folate intake (calculated as supplemental folic acid + 0.6 * folate intake from foods).
Table 3 shows the general characteristics of newborns and women (categorical vari-
ables). Statistically significant differences by sex were observed only when newborns were
classified as SGA, AGA or LGA based on height. The remaining anthropometric measures
failed to show significant differences. About 80% of women reported alcohol consumption
(any amount) at some point during their pregnancy, while a far lower percentage (around
16%) reported smoking during the pregnancy. Sixty-five percent and 77% of women had
total folate intake over 600 µg, the recommended dose for the first and third trimester of
pregnancy, respectively. Gestational diabetes was found to be more frequent in women
who gave birth to male infants (p = 0.006).
Table 4 Mean anthropometric measures, weight, height, head circumference, chest
circumference, weight index and gestational age, of male and female newborns did not
show significant differences when compared by maternal MTHFR(677)C>T genotypes
(Table 4).
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Table 4. Differences in arithmetic and geometric means of anthropometric measurements (stratified by sex) according to the
maternal genetic polymorphism of MTHFR(677)C>T.





CC CT TT p-Value CC CT TT p-Value
Weight (g)
AM 3402.69 3376.20 3367.50
0.840
3259.27 3214.58 3210.27
0.636(SD) (482.26) (457.95) (394.47) (413.74) (449.90) (421.19)
GM 3365.69 3344.17 3345.03 3229.50 3181.07 3180.76
Height(cm)
AM 50.91 50.97 51.2
0.436
50.26 50.25 50.07
0.800(SD) (2.32) (2.10) (2.04) (2.25) (2.39) (2.08)
GM 50.86 50.93 51.22 50.21 50.20 50.03
Head
circumference (cm)
AM 34.02 34.02 33.83
0.597
33.60 33.33 33.44
0.301(SD) (1.53) (1.65) (1.26) (1.51) (1.57) (1.58)
GM 33.99 33.98 33.81 33.57 33.29 33.40
Chest
circumference (cm)
AM 33.20 33.16 33.25
0.795
32.82 32.64 32.73
0.602(SD) (1.80) (1.90) (1.75) (1.70) (1.72) (2.08)
GM 33.15 33.11 33.20 32.77 32.59 32.66
Weight index
(gr/cm3)
AM 2.57 2.54 2.51
0.242
2.56 2.53 2.55
0.681(SD) (0.25) (0.26) (0.22) (0.25) (0.27) (0.23)
GM 2.56 2.53 2.50 2.55 2.52 2.54
Gestational age
(weeks)
AM 39.49 39.65 39.57
0.687
39.63 39.44 39.45
0.423(SD) (1.48) (1.45) (1.44) (1.43) (1.49) (1.39)
GM 39.46 39.62 39.54 39.61 39.41 39.42
Newborn anthropometric measures are presented as arithmetic mean (AM) and 95% confidence interval (CI 95%), and geometric mean
(GM). Means for each genotype were compared by ANOVA in the case of weight and weight index (normally distributed variables) and by
Kruskal–Wallis test for the remaining anthropometric measures (variables lacking a normal distribution).
The association between anthropometric measures of newborns (categorical variables)
stratified by sex and maternal MTHFR(677)C>T genotype is shown in Table 5. Infants
born LGA according to weight were significantly associated with the maternal genotype
CT or CT/TT in both sexes. While female infants whose mother carried a T allele had an
increased risk of being LGA (OR = 2.09 CI 95% (1.00;4.36) p < 0.05) male infants born to
mothers carrying the T allele had a protective effect against LGA condition (OR = 0.52 CI
95% (0.26;1.06) p < 0.1). The same was observed when maternal genotype was CT or TT for
female (OR = 1.89 CI 95% (0.94;3.81) p < 0.1) and male infants (OR = 0.49 CI 95% (0.25;0.93)
p < 0.05).
Maternal genotype TT was also a protective factor for being born LGA according to
height, but only in female infants (OR = 0.36 CI 95% (0.15;0.89) p < 0.05).
Although male infants had an increased risk of being born SGA according to weight
index when their mothers had the heterozygous CT genotype (p < 0.1; OR = 1.60 CI 95%
(0.97;2.62)), although statistical significance did not remain in the adjusted model. In the
case of female premature infants, an increased risk of being born SGA was found for the
maternal CT genotype (OR = 5.01 CI 95% (0.85;29.59) p < 0.1) or CT/TT (OR = 4.32 CI 95%
(0.79;23.58) p < 0.1).
Head and chest circumferences did not show significant associations with the maternal
genotype (p > 0.1)
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Table 5. Associations between anthropometric measures at birth and maternal MTHFR(677)C>T genotype.
Female Infants Male Infants
SGA LGA SGA LGA
















































































































CC 15/114 Ref. Ref. 1/50 Ref. Ref. 13/129 Ref. Ref. 1/129 Ref. Ref.
CT 20/134 1.13(0.56;2.32)
1.07



















(0.21;2.30) 0/50 no value no value
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Table 5. Cont.
Female Infants Male Infants
SGA LGA SGA LGA


















CC 4/126 Ref. Ref. - - - 4/139 Ref. Ref. - - -
CT 4/150 0.84(0.21;3.43)
0.50




(0.60;20.92) - - -
TT 4/51 2.47(0.60;10.26)
3.29




(0.25;20.73) - - -
CT o TT 8/201 1.25(0.37;4.25)
1.17




(0.58;16.56) - - -
Weight index 5






















(0.57;2.28) 0/36 no value no value















Prematurity 6 (yes/no) (yes/no)
CC 2/128 Ref. Ref. - - - 6/137 Ref. Ref. - - -
CT 8/146 3.51(0.73;16.82)
5.01




(0.25;2.67) - - -
TT 2/53 2.42(0.33;17.60)
3.03




(0.19;5.05) - - -
CT o TT 10/199 3.22(0.69;14.92)
4.32




(0.28;2.56) - - -
* p < 0.1, ** p < 0.05. 1 Model adjusted for BMI at 36 weeks of gestation, hypertension, alcohol consumption and tobacco smoking during pregnancy. 2 Model adjusted for BMI at 36 weeks of gestation,
hypertension and maternal age. 3 Model adjusted for maternal age, recommended folate intake in 2nd and 3rd trimester of pregnancy and tobacco smoking during pregnancy. 4 Model adjusted for hypertension,
alcohol consumption during pregnancy and vitamin B12 intake in 2nd and 3rd trimester of pregnancy. 5 Model adjusted for BMI at 36 weeks of gestation, tobacco smoking during pregnancy and vitamin B12
intake in 2nd and 3rd trimester of pregnancy. 6 Model adjusted by hypertension and tobacco smoking during pregnancy.
Nutrients 2021, 13, 831 11 of 15
4. Discussion
In this study of pregnant women from Southern Spain with adequate folate nutritional
status, the MTHFR(677)C>T genetic polymorphism was associated with infant anthropom-
etry at birth and with a higher risk of SGA in female premature infants.
The frequency of maternal MTHFR 677T allele of our population (38%) was in agree-
ment with those reported for other populations, which also found no differences in the
distribution of genotypes and allele frequencies by sex [28]. Newborns only differed in
anthropometric measures of weight, height, head and chest circumferences as expected
according to sex.
The common MTHFR genetic polymorphism (677)C>T (rs1801133) leads to the syn-
thesis of a thermolabile enzyme, which may lead to high levels of homocysteine in the
blood (hyperhomocysteinemia) that have been considered a risk factor for several adverse
outcomes at birth. Previous studies have shown that the cytosine (C) to thymine (T) transi-
tion at position 677 within exon 4 of the MTHFR gene, which results in an alanine to valine
amino acid substitution in the protein, is responsible for reducing enzyme activity in the
homozygous TT and heterozygouw CT allelic variants by 60% and 30% of the CC genotype,
respectively [12,29]. This reduced catalytic activity of MTHFR declines the production of
5-MTHF from folate. 5-MTHF is the active and circulating form of folate, which is a methyl
donor for the conversion of homocysteine to methionine [12,30,31]. When methionine is
converted back to homocysteine, the methyl group released causes DNA methylation [12].
Vitamin B12 also plays an important role in this cycle, as it is a necessary cofactor in the
enzymatic conversion of homocysteine to methionine [32,33]. Other B vitamins, which
have not been as extensively studied such as B6, play an interesting role in the one-carbon
cycle. It should be noted that there are innumerable interrelations between B vitamins and
may be influenced by genetic determinants, including some polymorphisms such as the
one mentioned in this study [34].
In the absence of adequate folate availability, methionine production decreased, ho-
mocysteine accumulates and methylation reactions are compromised. Thus, folate, as a
donor of carbon units in the one-carbon cycle, participates in the synthesis of nucleic acids
as well as in the methylation of DNA sequences, including key placental genes. Folic acid
supplementation during early pregnancy is intended to prevent the possible pathological
conditions that a folate deficiency could cause [35–37]. This deficiency might be due to a
poor dietary intake of green vegetables, fruits, legumes and animal origin food products or
to a decreased bioavailability of folate due to a genetic background, for example, carriers
or the unfavorable genotypes MTHFR-677CT/TT who may need supplemental folate
intake [24,38–41].
The association between the maternal MTHFR(677)C>T genetic polymorphism and
adverse birth outcomes has been previously reported in different populations, especially
in pregnant women with inadequate folate intake. A recent meta-analysis showed that
the maternal MTHFR(677)-T allele, and specifically carriers of the TT genotype, were
associated with an increased risk of preterm birth and with low birth weight under most of
the genetic models [18]. That study concluded that screening for MTHFR(677)C>T genetic
polymorphism might play a key role for prevention of preterm birth and low birth weight
in high risk pregnant women, especially with insufficient folate intake [18].
In our population, only 1% of pregnant women did not intake a folic acid supplements
before or during the first trimester of pregnancy. The vast majority (99%) of pregnant
women received a supplement of 400 or 500 micrograms of folic acid per day, which in
almost all cases also included 2 to 2.6 micrograms of vitamin B12. The same folate intake
was maintained during the third trimester of pregnancy. Thereby, the mean total folate
intake was considered adequate, as it falls within the recommended dose of 600–1000
micrograms per day (679.79 µg/day (95% CI 669.78–689.80) during first trimester and
655.30 µg/day 95% CI 643.27–667.33 during the third trimester). This means that 77 and
65% of women had total folate intakes over the minimum recommended dose during
the first and third trimester, respectively. Vitamin B12 total intake was always above the
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recommended dose of 2.6 µg/day during pregnancy. A daily folic acid intake of 400 µg
per day has been reported to be sufficient to override the effects of unfavourable MTHFR
genotypes on homocysteine and plasma folate levels [42]. This may be the case in our
population, considering folic acid supplementation and background folate intake data, as
well as high Vitamin B12 consumption. Despite this adequate folate status maintained
throughout pregnancy we observed an association between heterozygous or homozygous
carriers of the MTHFR(677)T variant and SGA and LGA categories according to weight,
height and preterm birth. It appears that unfavorable MTHFR(677) genotypes require addi-
tional factors to overcome the metabolic defects caused by low MTHFR activity, otherwise
the genetic factor by itself would impair fetal growth. An experimental study showed that
folate supplementation in a cell line with low MTHFR activity did not significantly increase
the concentration of 5-MTHF, the biologically active folate, when compared with normal
MTHFR activity cells [43]. Thus, the metabolic defects caused by genetic polymorphisms
of the gene encoding the MTHFR enzyme may require supplemental 5-MTHF to overcome
such defects [43]. Moreover, previous studies have demonstrated the excellent safety
profile for the Calcium L-5-methyltetrahydrofolic acid (L-5-MTHF-Ca). Thus, it would
be interesting to assess in future studies a supplementation with L-5-MTHF-Ca as a safe
alternative to 5-MTHF as a source of folate, in particular for pregnant women carrying the
MTHFR(677)T variant [44].
Altered methylation pattern in placental genes involved in fetal growth could be one of
the biological mechanisms that would explain the association between the MTHFR(677)C>T
genetic polymorphism and anthropometric measures at birth. Hypomethylation of DNA
sequences of that gene, which usually are imprinted, could lead to overgrowth. That
is, placental hypomethylation may indiscriminately activate various imprinted and not
imprinted genes, including those involved in fetal growth. Likewise, in utero exposure
to adverse environmental conditions might impair DNA methylation through altered
availability of methyl donors provided by the one-carbon pathway and this effect could be
sex-specific. Drake et al., observed that maternal smoking was associated with sex-specific
alterations in fetal liver vitamin B12, plasma homocysteine and expression of enzymes in
the one-carbon cycle in fetal liver [45]. These mechanisms could in part explain the sex
specific differences observed in our study, where mothers having a CT or CT/TT genotype
had an increased risk of having an LGA female infant (according to weight) while it had a
protective effect for LGA male infants.
Alterations in DNA methylation have been proposed as the possible link between
MTHFR(677) unfavorable variant and increased risk of pregnancy complications Del Gob-
blo et al. [46]. That study did not find evidence for an association of the MTHFR(677)C>T
polymorphism with altered placental DNA methylation using both genome-wide and
site-specific approaches, but described a tendency for increased MTHFR(677)TT genotype
in placentas from pregnancies complicated by pathologies such as preeclampsia and in-
trauterine growth restriction [45]. The inconsistencies in the results reported by different
authors reveal that the effect of the MTHFR(677) polymorphism on DNA methylation
is complex, and may likely be influenced by other polymorphisms in genes involved in
the one-carbon cycle, and by the complex interactions between all them and also with an
intrauterine adverse environment.
The current study has a number of strengths and limitations. The major limitation
was the semi-quantitative assessment of the maternal dietary folate intake obtained by
questionnaires. We do not have data on biomarkers in biological samples, which otherwise
is seldom used in cohort studies in which information of food and vitamins consumption
is commonly obtained through food frequency questionnaires. The questionnaire we used
was adapted from one previously validated in a Mediterranean population of pregnant
women. In this validation study significant correlations were observed between total folate
and vitamin B12 intake estimated by FFQ and plasma folate and vitamin B12 concentrations
(r = 0.53, p < 0.01 and r = 0.12, p < 0.05, respectively), and a percentage of agreement of 72%
and 55%, respectively [23], which ensures the suitability of its use. Moreover, most of the
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study population was made up of Spaniards, which limits generalization of results across
ethnicities. In any case, this homogeneity avoids genetic stratification due to geographical
origin. Another limitation of this study is the lack of data on fetal MTHFR(677)C>T
genotype. Because of the interplay of maternal and fetal genotypes, the missing fetal data
prevent us from assessing the relative fetal contribution to the observed effect.
5. Conclusions
This study showed that maternal MTHFR(677)C>T genetic polymorphisms is associ-
ated with infant’s anthropometry at birth. Considering the potential effects of low folate
availability due to diet and/or genetic background, it is necessary to continue emphasizing
the importance of following the dietary recommendations during pregnancy, or at least to
inform pregnant women on the risk of not following such recommendations. It is crucial to
raise awareness on this issue, even in populations where folic acid supplementation has
been implemented for years.
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